Custom Digital Twin Atlas Development
Build a proprietary reference atlas combining public data, our biobanks, and your data
The Challenge
Building Atlas Internally Takes Years
Creating a comprehensive disease atlas from scratch requires extensive data curation, harmonization, analysis pipeline development, and annotation -- representing a substantial multi-year effort with significant FTE and infrastructure investment.
Fragmented Public Data
Dozens of public datasets exist but with inconsistent platforms, batch effects, missing clinical annotations. Pharma teams lack bioinformatics capacity to integrate them.
No Drug Connectivity Integration
Without large-scale preclinical response profile integration, you can't characterize compound-biology relationships across patient subgroups—a major missed opportunity.
Static Atlas Becomes Outdated
Disease biology evolves, new subtypes discovered, therapies change. Internal atlases built once become obsolete without ongoing curation and updates.
"We spent significant time building an internal myeloma atlas from public data. By the time we finished, new large cohorts had been published and our atlas was already outdated. We should have outsourced this."
The Helomnix Solution
A Digital Twin Atlas is a structured reference landscape that maps patient molecular profiles into a shared coordinate space, annotated with preclinical response profiles and functional dependency data. Helomnix builds turnkey Digital Twin Atlases combining: (1) curated public cohorts (MM, AML, DLBCL with clinical outcomes), (2) our proprietary multi-omics biobanks, and (3) YOUR proprietary data (trial samples, biomarker cohorts). Delivered on an accelerated timeline compared to building internally.
Each atlas is annotated with comprehensive drug response signatures from large-scale perturbational reference libraries and gene essentiality annotations, enabling immediate drug connectivity analysis and target validation—capabilities most pharma atlases lack.
The atlas serves as your perpetual reference map for: (1) virtual cohort benchmarking (project molecular profiles onto the reference landscape), (2) biomarker discovery, (3) compound rescue (identify subgroups with distinct vulnerability profiles), and (4) competitive landscape analysis (compare molecular coverage of your pipeline to existing therapies).
Unique Differentiator
We provide a living atlas with quarterly updates as new public datasets emerge. Your atlas stays current without dedicating internal FTEs to ongoing curation. Includes drug connectivity and gene essentiality data from day one.
How It Works
Data Aggregation
We curate and integrate public multi-omics cohorts, our proprietary biobanks, and your proprietary data. Harmonize platforms, correct batch effects, standardize clinical annotations.
Digital Twin Generation
Apply our Multi-Modal Integration Engine to create unified patient digital twins. Project all patients onto a 2D Digital Twin Map™ using topology-preserving dimensionality reduction for visual clustering by molecular similarity.
Drug & Essentiality Annotation
Integrate comprehensive drug response signatures and gene essentiality profiles. Annotate each patient cluster with compound alignment profiles and functional vulnerabilities.
Atlas Deployment & Training
Deploy atlas as interactive web application with API access. Train your team on: virtual trial benchmarking, biomarker discovery, drug repurposing, target validation use cases.
Real-World Application
A pharma partner developing multiple myeloma therapies needed a comprehensive reference atlas to: (1) benchmark trial candidates, (2) discover biomarkers, (3) identify drug repurposing opportunities across their pipeline.
Before
Build internal atlas: Extended timeline with substantial FTE and infrastructure investment. No preclinical response profile or gene essentiality integration planned due to complexity.
After
Helomnix built custom MM Digital Twin Atlas on an accelerated timeline at a fraction of the internal cost. Included public, proprietary, and biobank sources with comprehensive preclinical response profiles and gene essentiality annotations.
Outcome
Reduced development time significantly. Used atlas to identify a previously uncharacterized subgroup with a distinct vulnerability profile, supporting compound rescue analysis. Discovered new biomarker associations. Atlas now central to all MM pipeline decisions.
Value to Your Organization
Development Cost Efficiency
Helomnix atlas development costs substantially less than building internally (extended timelines of FTEs, infrastructure, licenses).
Time to Deployment
Receive production-ready atlas on an accelerated timeline vs. extended internal development. Start making data-driven decisions substantially earlier.
Living Atlas Updates
Quarterly updates with new public datasets and drug annotations keep your atlas current without dedicating internal FTEs to curation.
Our Methodology
Data Inputs
- Public multi-omics cohorts (curated from major repositories)
- Your proprietary trial samples (RNA-seq, scRNA-seq, proteomics)
- Helomnix proprietary biobanks (with clinical outcome annotations)
- Clinical annotations (diagnosis, stage, treatment, outcomes)
- Drug response data (if available)
AI/ML Techniques
- Batch effect correction and cross-platform harmonization
- Platform harmonization and normalization
- Multi-Modal Integration Engine for digital twin generation
- Topology-preserving dimensionality reduction for Digital Twin Map™ visualization
- Large-scale perturbational reference signature integration
- Gene essentiality and functional dependency annotation
- Clinical outcome correlation and survival analysis
Deliverables
- Interactive Digital Twin Atlas web application
- Digital Twin Map™ visualization (2D patient clustering)
- Comprehensive drug response profiles per patient cluster
- Gene essentiality profiles and synthetic lethal vulnerabilities
- Biomarker signatures for major patient subgroups
- API access for programmatic queries
- Atlas user guide and team training (2-day workshop)
- Quarterly update reports with new data integration
Discuss a Translational Application
We welcome discussions about how this approach can support your translational research.